Young Chan Kim
Lecturer in Clinical Medicine; Senior Postdoctoral Fellow; Junior Research Fellow (JRF) at Wolfson College; NHS Doctor
I am a Junior Research Fellow (JRF) at Wolfson College, a Senior Postdoctoral Fellow at Oxford Vaccine Group (OVG) and a NHS doctor.
I completed a BSc degree in Biochemistry from Imperial College London and my medical degrees (BMBS, BMedSci and MRes) from the University of Nottingham. I then spent few years working in junior doctor posts before coming to Oxford to start a DPhil in Clinical Medicine (Somerville College). I have always been very keen on combining clinical medicine with a career in research. My DPhil studies focused on vaccine development against arthropod-borne viruses supported by Innovate UK funding. I was awarded the James S Porterfield Prize in International Virology 2016 to support my work on Zika virus in Mexico.
More recently, I was awarded highly prestigious NDM Graduate Student Prize 2020 (Overall Prize Winner) for my overall performance during my DPhil degree and a NIHR Oxford BRC Grant to support my research as a Postdoctoral Research Scientist at the Jenner Institute. I am now a Senior Postdoctoral Researcher at the Oxford Vaccine Group (OVG), a Junior Research Fellow (JRF) at Wolfson College, and a doctor in internal medicine in the Oxford University Hospitals NHS Foundation Trust.
López-Camacho C, et al. (2018). Rational Zika Vaccine Design via the Modulation of Antigen Membrane Anchors in Chimpanzee Adenoviral Vectors. Nat Commun, 9 (1), 1–11.
López-Camacho C & Kim Y C, et al. (2019). Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus. Viruses, 11 (4).
Kim Y C, et al. (2020). COVID-19 Vaccines: Breaking Record Times to First-in-Human Trials. NPJ Vaccines, 5, 34.
Kim Y C, et al. (2020). Evaluation of Chimpanzee Adenovirus and MVA Expressing TRAP and CSP from Plasmodium Cynomolgi to Prevent Malaria Relapse in Nonhuman Primates. Vaccines (Basel), 8 (3).
Folegatti P, et al. (2021). A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nat Commun. 12, 4636 2021.